<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">During the summer of 1989, an epidemic of what was called “
 <italic>eosinophilia</italic>-
 <italic>myalgia syndrome</italic>” (EMS) was observed in New Mexico (affecting around 1500 individuals, with 36 deaths): the patients presented eosinophilia and first complained of intense myalgia, followed by chronic cutaneous lesions, progressive PN and myopathy [
 <xref ref-type="bibr" rid="CR82">82</xref>]. EMS was associated with ingestion of 
 <sc>l</sc>-tryptophan (L-TRP) contained in dietary supplements manufactured in a Japanese plant using genetically engineered bacteria: removal of L-TRP from the market was followed by swift resolution of the EMS outbreak. Since the Food and Drug Administration (FDA) lifted the L-TRP import alert in 2005, only one sporadic cases of EMS was reported in 2011 [
 <xref ref-type="bibr" rid="CR83">83</xref>].
</p>
